Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Robert F. Kennedy Jr., Trump’s pick to be health secretary, is keeping his financial stake in major vaccine litigation ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...